MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
MaxCyte, Inc. (MXCT)
Company Research
Source: GlobeNewswire
ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/. Company management will also participate in the following investor conferences: 11th Annual BTIG Me
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.MarketBeat
- We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024GlobeNewswire
- Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]Seeking Alpha
MXCT
Earnings
- 3/12/24 - Beat
MXCT
Sec Filings
- 5/1/24 - Form ARS
- 4/26/24 - Form DEF
- 3/28/24 - Form 4
- MXCT's page on the SEC website